Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

WTWataru TakedaNINoriko IwakiWMWataru Munakata

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows CAR T-cell therapy outcomes in large B-cell lymphoma, indicating need for biomarker testing and treatment adaptation.

Key Points

  • Lactate dehydrogenase levels at progression average 267.5 IU/L, correlating with treatment response and outcomes.
  • Among treated patients, overall survival was 71% for those receiving bispecific antibodies compared to 23% for conventional therapies.
  • Analysis includes patients with large B-cell lymphoma who underwent CAR T-cell therapy at a single center from 2020 to 2025.
  • Loss of CD20 is a frequent occurrence and significantly affects treatment choices and prognosis, prompting repeat biopsy consideration.

Cite This Study

Takeda et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e583https://doi.org/10.1182/blood-2025-5440
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study2025
  2. 2Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment2025
  3. 3Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis2025
  4. 4CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party2025 · 1 citations
  5. 5Large B-cell lymphoma after CD19-CAR-T failure: Updated real-world outcomes, prognostic factors, and prediction models2025